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However, the fact that in another study we showed the functional
relevance of the same -786C allele in non-Japanese hypertensive
patients lends further support to the relevance of this polymor-
phism for cardiovascular disease in Caucasians (5).
Gian Paolo Rossi, MD, FACC, FAHA
Maurizio Cesari, MD
Achille C. Pessina, MD, PhD
Department of Clinical and Experimental Medicine
Clinica Medica 4 University Hospital
via Giustiniani, 2
35126 Padova
Italy
E-mail: gianpaolo.rossi@unipd.it
doi:10.1016/S0735-1097(03)00890-8
REFERENCES
1. Rossi GP, Cesari M, Zanchetta M, et al. The T-786C endothelial nitric
oxide synthase genotype is a novel risk factor for coronary artery disease
in Caucasian patients of the GENICA study. J Am Coll Cardiol
2003;41:930–7.
2. Alvarez R, Gonzalez P, Batalla A, et al. Association between the NOS3
(-786 T/C) and the ACE (I/D) DNA genotypes and early coronary
artery disease. Nitric Oxide 2001;5:343–8.
3. Nakayama M, Yasue H, Yoshimura M, et al. T-7863 C mutation in the
5-flanking region of the endothelial nitric oxide synthase gene is
associated with coronary spasm. Circulation 1999;99:2864–70.
4. Jeerooburkhan N, Jones LC, Bujac S, et al. Genetic and environmental
determinants of plasma nitrogen oxides and risk of ischemic heart
disease. Hypertension 2001;38:1054–61.
5. Rossi GP, Taddei S, Virdis A, et al. The T-786C and Glu298Asp
polymorphisms of the endothelial nitric oxide gene affect the forearm
blood flow responses of Caucasian hypertensive patients. J Am Coll
Cardiol 2003;41:938–45.
Response to Renin-Angiotensin System
Antagonists in Hypertensive Black Subjects
We read with interest the study by Flack et al. (1) which appeared
in the April 2, 2003, issue of the Journal. We commend the
researchers on investigating the effects of aldosterone antagonism
in the black population, who are traditionally underrepresented in
clinical trials. However, we have some concerns regarding the
characteristics of the study subjects.
First of all, we question the investigators’ use of weight, rather
than body mass index (BMI), as an anthropometric measurement.
Data from the Framingham Heart Study indicate that higher BMI
is a major determinant of inadequate blood pressure control with
antihypertensive medications (2). Though not statistically differ-
ent, both male and female subjects in the eplerenone group had
greater body weight than did those in the losartan group. Thus, we
are curious as to whether BMI differed between treatment groups
and, if so, whether these differences may have contributed to the
disparity in results between groups.
Second, the study included participants from both the U.S. and
Africa. The investigators do not report the percentage of black
participants who were from Africa versus those from the U.S. This
information is important in conferring the applicability of the
study findings to blacks in the U.S. Differences in environmental
factors have been reported among populations of African origin,
with higher BMI and greater sodium intake reported among
American blacks compared to African blacks (3). Similar to BMI,
sodium intake is a well-known factor influencing antihypertensive
response to renin-angiotensin system antagonists (4–6). Thus,
whether aldosterone antagonism would produce similar antihyper-
tensive effects in black Americans compared to black Africans is
uncertain.
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REPLY
We appreciate the questions raised by Humma and Adenekan
regarding the potential impact of body mass index (BMI) on the
blood pressure (BP)-lowering differences between eplerenone and
losartan in our recently published study. Also, the relevance of the
BP-lowering obtained in South African blacks to U.S. blacks was
raised.
There were 335 black participants in our trial; 260 (77.6%)
resided in the U.S. and 75 (22.4%) in South Africa. Black
participants were approximately evenly dispersed across treatment
groups with randomization to placebo, eplerenone, and losartan in
the following numbers (U.S. blacks/South African blacks): 1)
placebo (86/24); 2) eplerenone (83/25); and 3) losartan (91/26).
Blood pressure responses (SBP/DBP mm Hg) at 16 weeks (end of
trial) for blacks were: 1) placebo (3.7/4.8); 2) eplerenone
(13.5/10.2); and 3) losartan (5.3/6.0). Among South
African blacks, BP changes were: 1) placebo (1.1/4.1); 2)
eplerenone (11.6/10.1); and 3) losartan (0.8/3.6). The
overall rank-order of BP response was the same among U.S. and
South African blacks, although the absolute magnitude of change
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